GLP-1 assets add to growing late-stage MASH pipeline

More than 13 years after metabolic-associated steatohepatitis burst onto the scene following positive Phase II data from Intercept Pharmaceuticals Inc., the field has now swelled to more than 30 molecules in Phase II testing or later and two on the market. Adding to the bolus of programs are an influx of GLP-1 programs.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) was the first to market, with Rezdiffra resmetirom, and so far the early launch has exceeded consensus sales estimates. Madrigal reported $212.8 million in Rezdiffra sales last quarter— a 55% increase from $137.3 million in 1Q25 sales. The European Commission approved the THRB agonist for MASH last month, giving it further scope for growth...